American Diabetes Association 2019

The 79th Scientific Sessions of the American Diabetes Association will be held in San Francisco, California, June 7-11. The meeting offers researchers and healthcare professionals the opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care. Sign up for our daily email blasts on our registration page, and check back here during the conference for full coverage.
June 12, 2019
Selected technology news briefs from the 79th Scientific Sessions of the American Diabetes Association.
June 12, 2019
The final morning session of the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California, featured more cardiovascular and renal results from recent trials involving type 2 diabetes drugs.
June 11, 2019
Oral semaglutide, the first glucagon-like peptide 1 (GLP-1) receptor agonist in a pill, met safety benchmarks and reduced major cardiovascular (CV) events for high-risk patients with type 2 diabetes (T2D) in PIONEER 6, but did not achieve superiority, according to trial results presented at the 79th Scientific Sessions of the American Diabetes Association in San Francisco, California.
June 11, 2019
The connections among diabetes, cardiovascular (CV) disease, and kidney failure have been a theme of the 79th Scientific Sessions of the American Diabetes Association, which featured a joint session with the American Society of Nephrology.
June 11, 2019
The observational study will use information from 3 databases to compare the SGLT2 inhibitor to a competing class of therapy for type 2 diabetes. Early cardiovascular and safety data were presented Monday at the 79th Scientific Sessions of the American Diabetes Association.
June 09, 2019
Findings reported at the 79th Scientific Session of the American Diabetes Association in San Francisco, California, show the type 2 diabetes drug dapagliflozin significantly reduced the risk of renal decline, kidney failure, and renal death.
June 09, 2019
Results from a study involving adding sitagliptin and increasing doses of metformin for patients who cannot attain glycemic control show that as glycated hemoglobin increases, it becomes harder to reach targets.
June 09, 2019
Oral semaglutide would be the first non-injectable agent in the GLP-1 receptor agonist class; these drugs produce powerful glycemic control along with weight loss.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.